专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005020889A3 FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) 审中-公开
标题翻译：功能性流感病毒颗粒（VLPS）
公开(公告)号：WO2005020889A3
公开(公告)日：2005-12-29
申请号：PCT/US2004022001
申请日：2004-07-09
申请人： NOVAVAX INC , ROBINSON ROBIN A , PUSHKO PETER M
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： A61K39/145 , C07H21/04 , C07K14/11 , C12N7/01 , C12N7/04 , A61K39/12
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5258 , A61K2039/575 , A61K2039/70 , C07H21/04 , C07K14/005 , C12N7/00 , C12N2760/16023 , C12N2760/16034 , C12N2760/16122 , C12N2760/16123 , C12N2760/16134
摘要： Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.
摘要翻译：提供重组流感病毒蛋白，包括流行性感冒病毒，亚病毒颗粒，病毒样颗粒（VLP），VLP复合物和/或其任何部分作为流感病毒疫苗。本发明基于两种疫苗技术的组合：（1）本质安全的重组疫苗技术，和（2）高度免疫原性的，自组装的蛋白质大分子，其嵌入质膜中并且包含表现中和表位的流感病毒结构蛋白的多个拷贝在原生构象。更具体地说，本发明涉及由人流感病毒A型/悉尼/ 5/94（H3N2）和/或禽流感的重组结构蛋白构成的功能同型和异型重组流感病毒样颗粒（VLPs）的设计和生产病毒A型/香港/ 1073/99（H9N2）在杆状病毒感染昆虫细胞中的应用，并将其作为疫苗用于预防流感感染和作为病毒结构研究和临床诊断的实验室试剂。

2. 发明专利

JP2011046715A Functional influenza virus-like particle (vlp) 审中-公开
标题翻译：功能性流感病毒样颗粒（VLP）
公开(公告)号：JP2011046715A
公开(公告)日：2011-03-10
申请号：JP2010208644
申请日：2010-09-16
申请人： Novavax Inc , ノババックスインコーポレイテッド
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： C07K14/11 , A61K39/145 , A61P31/16 , A61P37/04 , C07H21/04 , C12N7/01 , C12N7/04 , C12N15/09 , C12P21/02 , G01N33/569
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5258 , A61K2039/575 , A61K2039/70 , C07H21/04 , C07K14/005 , C12N7/00 , C12N2760/16023 , C12N2760/16034 , C12N2760/16122 , C12N2760/16123 , C12N2760/16134
摘要： PROBLEM TO BE SOLVED: To provide high molecular protein constructs including (a) a first influenza virus M1 protein and (b) an additional structural protein, respectively. SOLUTION: The high molecular protein construct includes: an avian influenza virus A-type H9N2's HA protein coding sequence (GenBank registration number AJ404626); NA protein coding sequence (GenBank registration number AJ404629); M1 protein coding sequence (GenBank registration number AJ278646 protein); M2 protein coding sequence (GenBank registration number AF255363); and NP protein coding sequence (GenBank registration number AF255742). Another version of the high molecular protein construct includes: a human influenza virus A-type H3N2's HA sequence code (GenBank registration number AJ311466); and an NA sequence code (GenBank registration number AJ291403). COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：要解决的问题：提供高分子蛋白质构建体，分别包括（a）第一流感病毒M1蛋白和（b）另外的结构蛋白。解决方案：高分子蛋白质构建体包括禽流感病毒A型H9N2的HA蛋白编码序列（GenBank登记号AJ404626）; NA蛋白编码序列（GenBank注册号AJ404629）; M1蛋白编码序列（GenBank注册号AJ278646蛋白）; M2蛋白编码序列（GenBank注册号AF255363）; 和NP蛋白编码序列（GenBank注册号AF255742）。另一版本的高分子蛋白质构建体包括：人流感病毒A型H3N2的HA序列号（GenBank登记号AJ311466）; 和NA序列号（GenBank注册号AJ291403）。版权所有（C）2011，JPO＆INPIT

3. 发明专利

JP2015057447A 機能的インフルエンザウイルス様粒子（ＶＬＰ）审中-公开
标题翻译：功能性流感病毒样颗粒（VLP）
公开(公告)号：JP2015057447A
公开(公告)日：2015-03-26
申请号：JP2014258346
申请日：2014-12-22
申请人：ノババックスインコーポレイテッド , Novavax Inc , ノババックスインコーポレイテッド
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： C07K14/11 , A61K39/145 , A61K39/295 , A61K39/39 , A61P31/16 , A61P37/04 , C07H21/04 , C12N7/01 , C12N7/04 , C12P21/00 , G01N33/569
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5258 , A61K2039/575 , A61K2039/70 , C07H21/04 , C07K14/005 , C12N7/00 , C12N2760/16023 , C12N2760/16034 , C12N2760/16122 , C12N2760/16123 , C12N2760/16134
摘要：【課題】機能的インフルエンザウイルス様粒子(VLP)の提供。【解決手段】本発明により、トリインフルエンザウイルスA型H9N2のHAタンパク質コード配列(GenBank登録番号AJ404626)、NAタンパク質コード配列(GenBank登録番号AJ404629)、M1タンパク質コード配列(GenBank登録番号AJ278646タンパク質)、M2タンパク質コード配列(GenBank登録番号AF255363)およびNPタンパク質コード配列(GenBank登録番号AF255742)を含む高分子タンパク質構造物、ならびにヒトインフルエンザウイルスA型H3N2のHA配列コード(GenBank登録番号AJ311466)およびNA配列コード(GenBank登録番号AJ291403)を含む高分子タンパク質構造物が提供される。【選択図】なし
摘要翻译：要解决的问题：提供功能性流感病毒样颗粒（VLP）。解决方案：本发明提供包含禽流感病毒A型H9N2编码序列HA（GenBank登录号AJ404626），NA（GenBank Accession No AJ404629），M1（GenBank登录号AJ278646），M2（GenBank登录号AF255363）和NP（GenBank登录号AF255742）蛋白，以及包含人流感病毒A型H3N2编码序列的大分子蛋白质结构 HA（GenBank登录号AJ311466）和NA（GenBank登录号AJ291403）。

4. 发明专利

JP2013216685A Functional influenza virus-like particle (vlp) 审中-公开
标题翻译：功能性流感病毒样颗粒（VLP）
公开(公告)号：JP2013216685A
公开(公告)日：2013-10-24
申请号：JP2013141285
申请日：2013-07-05
申请人： Novavax Inc , ノババックスインコーポレイテッド
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： C07K14/11 , A61K39/145 , A61P31/16 , C07H21/04 , C07K19/00 , C12N7/01 , C12N7/04 , C12N15/09 , C12P21/02 , G01N33/569
CPC分类号： A61K39/145 , A61K39/12 , A61K2039/5258 , A61K2039/575 , A61K2039/70 , C07H21/04 , C07K14/005 , C12N7/00 , C12N2760/16023 , C12N2760/16034 , C12N2760/16122 , C12N2760/16123 , C12N2760/16134
摘要： PROBLEM TO BE SOLVED: To provide a macromolecular protein structure.SOLUTION: A macromolecular protein structure includes avian influenza virus type A H9N2 coding sequences for HA, NA, M1, M2, and NP proteins, and includes human influenza virus type A H3N2 coding sequences for HA and NA.
摘要翻译：要解决的问题：提供大分子蛋白质结构。解决方案：大分子蛋白结构包括HA，NA，M1，M2和NP蛋白的A型H9N2编码序列的禽流感病毒，包括人流感病毒A型H3N2编码序列对于HA和NA。

5. 发明专利

CA2532335C FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) 未知
公开(公告)号：CA2532335C
公开(公告)日：2014-11-18
申请号：CA2532335
申请日：2004-07-09
申请人： NOVAVAX INC
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： A61K39/12 , A61K39/145 , C07H21/04 , C07K14/11 , C12N7/01 , C12N7/04
摘要： Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

6. 发明专利

AU2011218606B2 Functional influenza virus-like particles (VLPS) 未知
公开(公告)号：AU2011218606B2
公开(公告)日：2012-01-12
申请号：AU2011218606
申请日：2011-08-26
申请人： NOVAVAX INC
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： C12N7/04 , A61K39/145 , C07H21/04 , C07K14/11 , C12N7/01
摘要： Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided 5 as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention 10 relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/I 073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus 15 structural studies and clinical diagnostics. ATGAATCCAAATCAAAAGATAATAGCACTTGGCTCTGTTTCTATAACTATTGCGACAATATG TTTACTCATGCAGATTGCCATCTTAGCAACGACTATGACACTACATTTCAATGAATGTACCA ACCCATCGAACAATCAAGCAGTGCCATGTGAACCAATCATAATAGAAAGGAACATAACAGAG ATAGTGCATTTGAATAATACTACCATAGAGAAGGAAAGTTGTCCTAAAGTAGCAGAATACAA GAATTGGTCAAAACCGCAATGTCAAATTACAGGGTTCGCCCCTTTCTCCAAGGACAACTCAA TTAGGCTTTCTGCAGGCGGGGATATTTGGGTGACAAGAGAACCTTATGTATCGTGCGGTCTT GGTAAATGTTACCAATTTGCACTTGGGCAGGGAACCACTTTGAACAACAAACACTCAAATGG CACAATACATGATAGGAGTCCCCATAGAACCCTTTTAATGAACGAGTTGGGTGTTCCATTTC ATTTGGGAACCAAACAAGTGTGCATAGCATGGTCCAGCTCAAGCTGCCATGATGGGAAGGCA TGGTTACATGTTTGTGTCACTGGGGATGATAGAAATGCGACTGCTAGCATCATTTATGATGG GATGCTTACCGACAGTATTGGTTCATGGTCTAAGAACATCCTCAGAACTCAGGAGTCAGAAT GCGTTTGCATCAATGGAACTTGTACAGTAGTAATGACTGATGGAAGTGCATCAGGAAGGGCT GATACTAAAATACTATTCATTAGAGAAGGGAAAATTGTCCACATTGGTCCACTGTCAGGAAG TGCTCAGCATGTGGAGGAATGCTCCTGTTACCCCCGGTATCCAGAAGTTAGATGTGTTTGCA GAGACAATTGGAAGGGCTCCAATAGACCCGTGCTATATATAAATGTGGCAGATTATAGTGTT GATTCTAGTTATGTGTGCTCAGGACTTGTTGGCGACACACCAAGAAATGACGATAGCTCCAG CAGCAGTAACTGCAGGGATCCTAATAACGAGAGAGGGGGCCCAdGAGTGAAAGGGTGGGCCT TTGACAATGGAAATGATGTTTGGATGGGACGAACAATCAAGAAAGATTCGCGCTCTGGTTAT GAGACTTTCAGGGTCGTTGGTGGTTGGACTACGGCTAATTCCAAGTCACAAATAAATAGGCA AGTCATAGTTGACAGTGATAACTGGTCTGGGTATTCTGGTATATTCTCTGTTGAAGGAAAAA CCTGCATCAACAGGTGTTTTTATGTGGAGTTGATAAGAGGGAGACCACAGGAGACCAGAGTA TGGTGGACTTCAAATAGCATCATTGTATTTTGTGGAACTTCAGGTACCTATGGAACAGGCTC ATGGCCCGATGGAGCGAATATCAATTTCATGTCTATATAA

7. 发明专利

AU2004268510B2 Functional influenza virus-like particles (VLPs) 未知
公开(公告)号：AU2004268510B2
公开(公告)日：2011-06-09
申请号：AU2004268510
申请日：2004-07-09
申请人： NOVAVAX INC
发明人： PUSHKO PETER M , ROBINSON ROBIN A
IPC分类号： C07H21/04 , A61K39/145 , C07K14/11 , C12N7/01 , C12N7/04
摘要： Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

8. 发明专利

MXPA06000469A PARTICULAS FUNCIONALES SIMILARES AL VIRUS DE LA INFLUENZA (VLPS). 未知
公开(公告)号：MXPA06000469A
公开(公告)日：2006-08-23
申请号：MXPA06000469
申请日：2004-07-09
申请人： NOVAVAX INC
发明人： PUSHKO PETER M
IPC分类号： A61K20060101 , A61K39/12 , A61K39/145 , C07H21/04 , C07K14/11 , C12N7/01 , C12N7/04 , A61K00/00
摘要： Se describen las proteinas recombinantes del virus de la influenza, que incluyen capsomeros de influenza, particulas subvirales, particulas similares al virus (VLP), complejos de VLP, y/o cualesquiera porciones de las mismas, que son proporcionadas como una vacuna para el virus de la influenza. La invencion esta basada en la combinacion de dos tecnologias de vacuna: (1) la tecnologia de vacuna recombinante intrinsecamente segura, y (2) las macromoleculas de proteina auto-ensambladas, altamente inmunogenicas, incrustadas en membranas plasmaticas, y comprendidas de copias multiples de proteinas estructurales del virus de la influenza, que muestran epitopos neutralizadores en conformaciones nativas. Mas especificamente, esta invencion se refiere al diseno y produccion de particulas similares al virus de la influenza, recombinantes, homotipicas y heterotipicas, funcionales (VLPs) comprendidas de las proteinas estructurales recombinantes del virus de la influenza humana tipo A/Sydney/5/94 (H3N2) y/o el virus de la influenza aviar tipo A/Hong Kong/1073/99 (H9N2) en celulas de insecto infectadas con el baculovirus, y su aplicacion como una vacuna en la prevencion de infecciones de influenza, y como un reactivo de laboratorio para estudios estructurales de virus y diagnosticos clinicos.

9. 发明专利

AU2004268510A1 Functional influenza virus-like particles (VLPs) 未知
公开(公告)号：AU2004268510A1
公开(公告)日：2005-03-10
申请号：AU2004268510
申请日：2004-07-09
申请人： NOVAVAX INC
发明人： PUSHKO PETER M , ROBINSON ROBIN A
IPC分类号： C07H21/04 , A61K39/145 , C07K14/11 , C12N7/01 , C12N7/04
摘要： Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

10. 发明专利

ES2422580T3 Partículas funcionales similares al virus (VLP) de la gripe 未知
公开(公告)号：ES2422580T3
公开(公告)日：2013-09-12
申请号：ES10010286
申请日：2004-07-09
申请人： NOVAVAX INC
发明人： ROBINSON ROBIN A , PUSHKO PETER M
IPC分类号： A61K39/145 , C07H21/04 , C07K14/005 , C07K14/11 , C12N7/00 , C12N7/01 , C12N7/04
摘要： Una composición para su uso como vacuna, dicha composición comprendiendo: i. una partícula similar a virus (VLP) que comprende proteínas estructurales de la gripe, donde las proteínas estructurales de la gripe de dicha VLP consisten en M1, HA y NA, donde la VLP se autoensambla en una célula hospedadora de una construcción recombinante; y ii. un vehículo o diluyente.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式